Preclinical
Orna announced first-ever data from its lead isCAR program that validates both the technology and its LNP delivery platform. BioSpace spoke with ORNA CEO Tom Barnes.
A group of scientists from the Babraham Institute in the United Kingdom has successfully rejuvenated skin cells by 30 years, observing several benefits of the functionally younger cells.
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
Researchers at the University of Illinois at Chicago have uncovered the possibility of utilizing gene editing to reverse a cause of anxiety and alcohol use disorder (AUD).
Context Therapeutics’ lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
Dianthus Therapeutics launched today with $100 million in Series A financing led by 5AM Ventures, Avidity Partners and Fidelity Research and Management. The company plans to tackle severe and rare autoimmune diseases by utilizing antibodies that target complements.
What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.
Bryostatin-1 increases antigen expression on the surface of cancer cells, enabling them to be seen and killed by IO agents.
AviadoBio is celebrating orphan drug designations from both the U.S. FDA and the European Commission for AVB-101, a gene therapy intended to treat frontotemporal dementia (FTD).
Pheast Therapeutics launched today with $76 million in Series A financing. Pheast is focused on developing cancer checkpoint therapies to fight malignant cells, focusing on ovarian and breast cancers.
PRESS RELEASES